Actis Biologics raising USD 500 million for expansion in Malaysia and India
Actis Biologics Pvt Ltd, the subsidiary of California-based Actis Biologics Inc, is raising funds in tune of USD 400 to 500 million for expansion activities especially in Malaysia and India.
ActoGeniX, a Dutch drug company whose lead candidate is focused on inflammatory bowel disease, has raised €13.5 million in second-round funding.